Carboxymethylcellulose encapsulated fingolimod, siRNA@ZnO hybrid nanocomposite as a new anti-Alzheimer's material-Reference-Cited by-同舟云学术

Carboxymethylcellulose encapsulated fingolimod, siRNA@ZnO hybrid nanocomposite as a new anti-Alzheimer's material

Published:2024 Issue:30 Volume:14 Page:22044-22055
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Aljohani Nuha B.¹²,Qusti Safaa Y.¹,Alsiny Madeeha¹,Aljoud Fadwa³,Aljohani Norah Bakheet⁴,Alsolami Eman S.⁵,Alamry Khalid A.⁵^ORCID,Hussein Mahmoud A.⁵⁶^ORCID

Affiliation:

1. Biochemistry Department, Faculty of Science, King Abdul Aziz University, Jeddah 21589, Kingdom of Saudi Arabia

2. Biochemistry Department, Faculty of Science, University of Tabuk, Tabuk, Kingdom of Saudi Arabia

3. Regenerative Medicine Unit, King Fahd Medical Research Centre, King Abdul Aziz University, Jeddah 21589, Saudi Arabia

4. King Abdul Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia

5. Chemistry Department, Faculty of Science, King Abdulaziz University, P.O. Box 80203, Jeddah 21589, Saudi Arabia

6. Chemistry Department, Faculty of Science, Assiut University, Assiut 71516, Egypt

Abstract

CMC-encapsulated fingolimod and siRNA@ZnO hybrid nanocomposite frameworks have been proven to prevent AD and improve AD treatment techniques as drug delivery carriers.

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA01965B

Reference39 articles.

1. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development

2. Neuroinflammation in Alzheimer's disease

3. Application of ZnO-Based Nanocomposites for Vaccines and Cancer Immunotherapy

4. Emerging nanopharmaceuticals

5. The amyloid hypothesis of Alzheimer's disease at 25 years